187 related articles for article (PubMed ID: 35605481)
1. Efficacy of cenobamate by focal seizure subtypes: Post-hoc analysis of a phase 3, multicenter, open-label study.
Rosenfeld WE; Ferrari L; Kamin M
Epilepsy Res; 2022 Jul; 183():106940. PubMed ID: 35605481
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of cenobamate for uncontrolled focal seizures: Post hoc analysis of a Phase 3, multicenter, open-label study.
Sperling MR; Abou-Khalil B; Aboumatar S; Bhatia P; Biton V; Klein P; Krauss GL; Vossler DG; Wechsler R; Ferrari L; Grall M; Rosenfeld WE
Epilepsia; 2021 Dec; 62(12):3005-3015. PubMed ID: 34633084
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Cenobamate for the Treatment of Focal Seizures in Older Patients: Post Hoc Analysis of a Phase III, Multicenter, Open-Label Study.
O'Dwyer R; Stern S; Wade CT; Guggilam A; Rosenfeld WE
Drugs Aging; 2024 Mar; 41(3):251-260. PubMed ID: 38446341
[TBL] [Abstract][Full Text] [Related]
4. Post hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: Effects of dose adjustments of concomitant antiseizure medications.
Rosenfeld WE; Abou-Khalil B; Aboumatar S; Bhatia P; Biton V; Krauss GL; Sperling MR; Vossler DG; Klein P; Wechsler R
Epilepsia; 2021 Dec; 62(12):3016-3028. PubMed ID: 34633074
[TBL] [Abstract][Full Text] [Related]
5. Post hoc analysis of a phase 3 study for treatment of uncontrolled focal seizures: Adjunctive cenobamate dose and seizure reduction by baseline seizure frequency.
Aboumatar S; Biton V; Wechsler R; Ferrari L; Rosenfeld WE
Epilepsy Res; 2022 Oct; 186():107014. PubMed ID: 36063589
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of adjunctive cenobamate based on number of concomitant antiseizure medications, seizure frequency, and epilepsy duration at baseline: A post-hoc analysis of a randomized clinical study.
Rosenfeld WE; Nisman A; Ferrari L
Epilepsy Res; 2021 May; 172():106592. PubMed ID: 33662894
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures.
Chung SS; French JA; Kowalski J; Krauss GL; Lee SK; Maciejowski M; Rosenfeld WE; Sperling MR; Mizne S; Kamin M
Neurology; 2020 Jun; 94(22):e2311-e2322. PubMed ID: 32409485
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of cenobamate for uncontrolled focal seizures in patients with previous epilepsy-related surgery: Post hoc analysis of a phase 3, multicenter, open-label study.
Abou-Khalil B; Aboumatar S; Klein P; Krauss GL; Sperling MR; Rosenfeld WE
Epilepsy Res; 2022 Aug; 184():106952. PubMed ID: 35671632
[TBL] [Abstract][Full Text] [Related]
9. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study.
Sperling MR; Klein P; Aboumatar S; Gelfand M; Halford JJ; Krauss GL; Rosenfeld WE; Vossler DG; Wechsler R; Borchert L; Kamin M
Epilepsia; 2020 Jun; 61(6):1099-1108. PubMed ID: 32396252
[TBL] [Abstract][Full Text] [Related]
10. Onset of efficacy and adverse events during Cenobamate titration period.
Steinhoff BJ; Ben-Menachem E; Brandt C; García Morales I; Rosenfeld WE; Santamarina E; Serratosa JM
Acta Neurol Scand; 2022 Sep; 146(3):265-275. PubMed ID: 35711112
[TBL] [Abstract][Full Text] [Related]
11. Reductions in concomitant antiseizure medication drug load during adjunctive cenobamate therapy: Post-hoc analysis of a subset of patients from a phase 3, multicenter, open-label study.
Aboumatar S; Ferrari L; Stern S; Wade CT; Weingarten M; Connor GS; Rosenfeld WE
Epilepsy Res; 2024 Feb; 200():107306. PubMed ID: 38340681
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of adjunctive perampanel 4 mg/d for the treatment of focal seizures: A pooled post hoc analysis of four randomized, double-blind, phase III studies.
Steinhoff BJ; Patten A; Williams B; Malhotra M
Epilepsia; 2020 Feb; 61(2):278-286. PubMed ID: 31944276
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial.
Krauss GL; Klein P; Brandt C; Lee SK; Milanov I; Milovanovic M; Steinhoff BJ; Kamin M
Lancet Neurol; 2020 Jan; 19(1):38-48. PubMed ID: 31734103
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of adjunctive cenobamate: Post-hoc analysis of study C017 in patients grouped by mechanism of action of concomitant antiseizure medications.
Brandt C; Sánchez-Álvarez JC; Steinhoff BJ; Milanov I; Serratosa JM
Seizure; 2022 Mar; 96():86-93. PubMed ID: 35168142
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of adjunctive cenobamate based on patient etiology: Post-hoc analysis of YKP3089C017 randomized clinical trial.
Xu J; Wei W; Liu Y; Ye H; Liu X
Seizure; 2024 May; 118():95-102. PubMed ID: 38652999
[TBL] [Abstract][Full Text] [Related]
16. Adjunctive use of cenobamate for pediatric refractory focal-onset epilepsy: A single-center retrospective study.
Varughese RT; Shah YD; Karkare S; Kothare SV
Epilepsy Behav; 2022 May; 130():108679. PubMed ID: 35381496
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: Open-label extension of a randomized clinical study.
French JA; Chung SS; Krauss GL; Lee SK; Maciejowski M; Rosenfeld WE; Sperling MR; Kamin M
Epilepsia; 2021 Sep; 62(9):2142-2150. PubMed ID: 34254673
[TBL] [Abstract][Full Text] [Related]
18. Long-term individual retention with cenobamate in adults with focal seizures: Pooled data from the clinical development program.
Sander JW; Rosenfeld WE; Halford JJ; Steinhoff BJ; Biton V; Toledo M
Epilepsia; 2022 Jan; 63(1):139-149. PubMed ID: 34813673
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of perampanel in generalized and focal to bilateral tonic-clonic seizures: A comparative study of Asian and non-Asian populations.
Nishida T; Lee SK; Wu T; Tiamkao S; Dash A
Epilepsia; 2019 Mar; 60 Suppl 1():47-59. PubMed ID: 30869168
[TBL] [Abstract][Full Text] [Related]
20. Cognitive and psychiatric adverse events during adjunctive cenobamate treatment in phase 2 and phase 3 clinical studies.
Krauss GL; Chung SS; Ferrari L; Stern S; Rosenfeld WE
Epilepsy Behav; 2024 Feb; 151():109605. PubMed ID: 38184949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
